Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase.
In this study, protein C (PC), protein S (PS), heparin cofactor II (HCFII), prothrombin fragment 1+2 (PF 1,2), thrombin-antithrombin III complex (TAT), von Willebrand factor (vWF) and thrombomodulin (TM) were investigated in 19 patients with acute lymphoblastic leukemia, (ALL) receiving combined chemotherapy including L-asparaginase (L-ASP) and high dose methylprednisolone (HDMP). HDMP was administered in doses of 30 mg/kg/day for 7 days, and 20 mg/kg/day for another 7 days. In order to evaluate the effect of HDMP on the hemostatic system, the 8 patients studied here received HDMP (30 mg/kg/day) therapy for 4 days before the combined chemotherapy. These parameters were also studied in 12 healthy children as a control group. PC levels were normal in the patients while PS levels were decreased both before and after combined chemotherapies. Patients with ALL have laboratory signs of coagulation activation such as PF 1,2, TAT prior to initiation of chemotherapy. With combined chemotherapy, TAT levels were found to be normal while PF1,2 were not. TM levels were found to be increased both before and after therapies whereas HCFII and vWF levels were not different from those of the control group. The short course of HDMP therapy did not prominently influence these hemostatic parameters. These results indicate that both the malignant process and the drugs used in combined chemotherapy cause a decrease in natural inhibitors and an increase in procoagulant activity and endothelial injury. These hemostatic changes may contribute to a thrombotic tendency in the patients with ALL.
Oner
A F
AF
Department of Pediatric Hematology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Gürgey
A
A
Kirazli
S
S
Okur
H
H
Tunç
B
B
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000990:Antithrombin III / Q000032:analysis; D001215:Asparaginase / Q000008:administration & dosage; D001798:Blood Proteins / Q000032:analysis*; D002648:Child; D002675:Child, Preschool; D005260:Female; D015844:Heparin Cofactor II / Q000032:analysis; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D010446:Peptide Fragments / Q000032:analysis; D010447:Peptide Hydrolases / Q000032:analysis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood* / Q000188:drug therapy*; D011486:Protein C / Q000032:analysis; D017293:Protein S / Q000032:analysis; D011516:Prothrombin / Q000032:analysis; D018180:Thrombomodulin / Q000097:blood; D014841:von Willebrand Factor / Q000032:analysis
D001798:Blood Proteins; D010446:Peptide Fragments; D011486:Protein C; D017293:Protein S; D018180:Thrombomodulin; C046193:antithrombin III-protease complex; C045879:prothrombin fragment 1.2; D014841:von Willebrand Factor; D015844:Heparin Cofactor II; D000990:Antithrombin III; D011516:Prothrombin; D010447:Peptide Hydrolases; D001215:Asparaginase; D008775:Methylprednisolone